Abstract 469P
Background
The advancements in treatment strategies for cancer in Adolescent and Young Adults (AYAs) and early diagnosis has led to an increase in the cure rate and an increase in the number of AYA cancer survivors. The AYA patient is defined as an individual 15 to 39 years of age at the time of initial cancer diagnosis. AYA cancer survivors are at increased risk of developing various physical and psychosocial issues which vary from those in older adults. There are very few integrated survivorship programmes for AYA cancer survivors in India and this is a huge unmet need.
Methods
This online survey was directed at oncologists from various major specialties in India, with an interest in the care of AYA cancer patients and survivors. Oncologists practicing in India were sent the survey questionnaire through Google link via e-mail. Data was collected in SPSS and descriptive statistics were performed.
Results
We received 100 responses from June 2021 to September 2021 from oncologists all over India. 85% of respondents were medical oncologists, with 59% working at academic centers. Among oncologists who responded to this survey, 74% reported that AYA cancer survivors comprised ≤ 25% of their clinical practice. Major issues faced by most of the survivors included fatigue, anxiety, depression, fear of recurrence, and financial and social issues. Although 88% of the respondents reported the need for a separate follow-up clinic for AYA survivors, only 32% had a dedicated cancer survivor clinic or program at their center. Half of these oncologists had a team of multidisciplinary care providers in their clinic. 58% of the respondents reported that more than 50% of the survivors have resumed their normal life.
Conclusions
There is an unmet need for specialized care for AYA cancer survivors in India. Only 32% of oncologists have dedicated clinics for AYA cancer survivors. There is a need to develop survivorship programs for AYA survivors across the country.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract